基于网络药理学方法的加味黄芪赤风汤治疗IgA肾病作用机制的研究

Abstract
Figure/Table
References (32)
Related Citation (15)

Download: PDF (2491 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the action target and potential mechanism of modified Huangqi Chifeng Decoction in treating IgA nephropathy by using network pharmacology knowledge. Methods Related chemical components of seven traditional Chinese medicine in modified Huangqi Chifeng Decoction and their action targets were screened out from the traditional Chinese medicine systems pharmacology database and analysis platform, and the active components of traditional Chinese medicine were screened out according to the corresponding standards. The disease targets related to IgA nephropathy were screened out through online Mendelian inheritance in man and Genecards database, and the common targets of modified Huangqi Chifeng Decoction and disease were calculated by R language. The corresponding regulatory network was plotted and constructed in Cytoscape research software. The String database was used to construct the corresponding protein-protein interaction network. The GO function and KEGG pathway enrichment analysis of the target were performed by R language to identify the possible key targets and key pathways. Results A total of 45 active components and 95 potential action targets were screened out from the modified Huangqi Chifeng Decoction. The treatment of IgA nephropathy may be related to the influence of the expression of albumin, interleukin (IL)-6, serine/threonine kinase 1, vascular endothelial growth factor A, and other genes. A total of 115 enrichment results were included in GO biofunction analysis, mainly involving phosphatase binding, heme binding, cytokine receptor binding and other processes. A total of 151 metabolic pathways were obtained by KEGG enrichment, mainly including AGE-RAGE signaling pathway, IL-17 signaling pathway, tumor necrosis factor signaling pathway, etc. Conclusion Based on the network pharmacology method, it is speculated that the modified Huangqi Chifeng Decoction can be used in the treatment of IgA nephropathy through various interventions, and has the therapeutic advantages of multiple components, multiple targets and multiple pathways, which provides theoretical reference for the future study of its pharmacodynamic substance basis and action mechanism.

Key words： Network pharmacology Modified Huangqi Chifeng Decoction IgA nephropathy Action mechanism

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Sijia ZHAO Mingming CHANG Meiying YU Yi WANG Rumeng ZHANG Yu

Cite this article:

MA Sijia ZHAO Mingming CHANG Meiying YU Yi WANG Rumeng ZHANG Yu. Study on the action mechanism of modified Huangqi Chifeng Decoction in the treatment of IgA nephropathy based on network pharmacology method[J]. 中国医药导报, 2021, 18(17): 29-35.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I17/29

[1] Barbour SJ，Reich HN. Risk Stratification of Patients With IgA Nephropathy [J]. Am J Kidney Dis，2012，59（6）：865-873.
[2] Donadio JV，Grande JP. IgA nephropathy [J]. N Engl J Med，2002，347（10）：738-748.
[3] McGrogan A，Franssen CF，de Vries CS. The incidence of primary glomerulonephritis worldwide：a systematic review of the literature [J]. Nephrol Dial Transplant，2011，26（2）：414-430.
[4] 蔡广研.IgA肾病临床诊治的一些新认识[J].中华肾病研究电子杂志，2016，5（5）：193-194.
[5] 唐洁，俞东容.浅析IgA肾病的中医治疗进展[J].中国中西医结合肾病杂志，2019，20（7）：645-646.
[6] 张秋，张昱.张昱运用大剂量黄芪治疗肾病蛋白尿的经验[J].中国中医药现代远程教育，2013，11（20）：104-105.
[7] 于子凯，李刘生，张昱，等.基于真实世界的加味黄芪赤风汤治疗IgA肾病的临床疗效评价[J].世界中医药，2018， 13（11）：2819-2822.
[8] 徐甜，连雅君，宋丹萍，等.基于生物分子网络调控研究麻黄附子细辛汤治疗过敏性鼻炎的作用机制[J].北京中医药大学学报，2019，42（6）：483-489.
[9] Berger J，Hinglais N. Intercapillary deposits of IgA-IgG [J]. J Urol Nephrol （Paris），1968，74（9）：694-695.
[10] Nabil Akash. Pathogenesis of IgA nephropathy：A Review [J]. Dialysis & Transplantation，2010，35（10）：612-616.
[11] Floege J，Eitner F. Current therapy for IgA nephropathy [J]. J Am Soc Nephrol，2011，22（10）：1785-1794.
[12] 王金虎.基于关联规则、实验研究探讨张昱主任医师治疗肾病综合征用药规律及机理研究[D].北京：北京中医药大学，2012.
[13] 张昱.加味黄芪赤风汤治疗慢性肾炎蛋白尿50例临床观察[J].中国医药导报，2007，4（36）：137-138.
[14] 常美莹，张昱.张昱运用加味黄芪赤风汤治疗慢性肾炎经验[J].中医药导报，2020，26（8）：93-96.
[15] 焦志娜，赵明明，张昱，等.加味黄芪赤风汤治疗IgA肾病蛋白尿的单病例随机对照研究[J].中国医药导报，2018， 15（1）：95-98.
[16] 赵明明.基于ROS-自噬通路调控的加味黄芪赤风汤抗AngⅡ诱导的肾小球足细胞损伤机制研究[D].北京：中国中医科学院，2018.
[17] 叶苗，刘丽仙，梁晓美.槲皮素对大鼠肾缺血再灌注损伤模型的保护作用[J].中国中西医结合肾病杂志，2019， 20（12）：1041-1043.
[18] 苏宁，李丰，赵平，等.黄芩苷调节DN大鼠肾脏局部生物活性物质的实验研究[J].世界中西医结合杂志，2010， 5（1）：22-24.
[19] 陈妮，韩鹏定，陈文，等.山奈酚对高糖诱导大鼠肾系膜细胞增殖的影响[J].四川大学学报：医学版，2017，48（4）：526-530，548.
[20] 舒红，王俭勤，王雅，等.黄芪毛蕊异黄酮对转化生长因子β1诱导内皮细胞转分化的影响[J].中华中医药杂志，2012，27（3）：753-755.
[21] Fujisawa H，Nakayama Y，Ueda K，et al. Role of AGEs-RAGE system in CKD-MBD [J]. Clin Calcium，2019，29（2）：193-198.
[22] Bates DO，Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors [J]. Vascul Pharmacol，2002，39（4/5）：225-237.
[23] Tammela T，Enholm B，Alitalo K，et al. The biology of vascular endothelial growth factors [J]. Cardiovasc Res，2005，65（3）：550-563.
[24] 田建军.IgA肾病患者血管内皮生长因子、内皮素-1水平变化及其临床意义研究[J].中国卫生检验杂志，2018， 28（19）：2376-2378，2398.
[25] 李卉，王林群，张雪荣，等.金水清合剂对IgA肾病大鼠TGF-β1、CTGF、VEGF表达的影响[J].世界中医药，2020， 15（7）：1016-1020.
[26] 安丽丽，郭登洲.PDGF、VEGF及受体Flk-1与IgA肾病相关性的研究进展[J].中国医药导报，2019，16（33）：36-39.
[27] 林芙君，刘秀英，张文竹，等.白细胞介素17在IgA肾病肾小管间质的表达及意义[J].临床肾脏病杂志，2010（10）：453-456.
[28] Lai X，Wei J，Ding X. Paeoniflorin Antagonizes TNF-α-Induced L929 Fibroblastoma Cells Apoptosis by Inhibiting NF-κBp65 Activation [J]. Dose Response，2018，16（2）：1559325818774977.
[29] 王春波.湿疹患者外周血IL-17和IL-23水平及白芍总苷治疗前后的变化[J].中国医药科学，2015，5（8）：49-50，54.
[30] 冯晓丽.HCMV、AdV和HBV抗原在IgA肾病患者肾组织中的表达及其临床意义[J].现代医用影像学，2018， 27（5）：1639-1640.
[31] Str?覽?覽t K，de Klark R，Gredmark-Russ S，et al. Infection with Human Cytomegalovirus Alters the MMP-9/TIMP-1 Balance in Human Macrophages [J]. J Virol，2009，83（2）：830-835.
[32] 王建中，陈香美，师锁柱，等.基质金属蛋白酶-9和金属蛋白酶组织抑制物-1在IgA肾病肾组织中的表达[J].中华内科杂志，2002，41（2）：75-78.